We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

16 hedge funds and large institutions have $561K invested in Evofem Biosciences, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

95% more capital invested

Capital invested by funds: $287K → $561K (+$273K)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

14% more funds holding

Funds holding: 14 → 16 (+2)

Holders
16
Holders Change
+2
Holders Change %
+14.29%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$46.3K
2
FPF
FNY Partners Fund
New York
+$33.7K
3
Citadel Advisors
Citadel Advisors
Florida
+$20.4K
4
Millennium Management
Millennium Management
New York
+$16.1K
5
Renaissance Technologies
Renaissance Technologies
New York
+$15.4K

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$20K
2
UBS AM
UBS AM
Illinois
-$5.06K
3
Morgan Stanley
Morgan Stanley
New York
-$1.43K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$779
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$168K +$46.3K +357 +44%
UBS AM
2
UBS AM
Illinois
$145K -$5.06K -39 -4%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$58K +$389 +3 +0.7%
FPF
4
FNY Partners Fund
New York
$37K +$33.7K +260 New
Goldman Sachs
5
Goldman Sachs
New York
$36K +$8.69K +67 +37%
Citadel Advisors
6
Citadel Advisors
Florida
$23K +$20.4K +157 New
Millennium Management
7
Millennium Management
New York
$18K +$16.1K +124 New
Northern Trust
8
Northern Trust
Illinois
$17K +$14.9K +115 New
Renaissance Technologies
9
Renaissance Technologies
New York
$17K +$15.4K +119 New
BlackRock
10
BlackRock
New York
$15K +$13.2K +102 New
Deutsche Bank
11
Deutsche Bank
Germany
$10K +$9.86K +76 New
Morgan Stanley
12
Morgan Stanley
New York
$8K -$1.43K -11 -16%
WAS
13
WESPAC Advisors SoCal
California
$4.8K – – –
UBS Group
14
UBS Group
Switzerland
$3K – – –
LTFS
15
Ladenburg Thalmann Financial Services
Florida
$1K – – –
ARTA
16
A.R.T. Advisors
New York
– -$20K -203 Closed
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
– -$779 -6 Closed

EVFM Hedge Fund Activity: Q1 2017 in Review

16 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2017, worth a combined $561K — up 95% from $287K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new EVFM positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $46.3K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $20K sold.

  • 16 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2017, up from 14 in Q4 2016.
  • Funds reported $561K of Evofem Biosciences, Inc. Common Stock stock for Q1 2017, up 95% quarter-over-quarter.
  • 7 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2017 and 2 closed out, a net change of +5 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2017 was Vanguard Group, an estimated $46.3K added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2017 was A.R.T. Advisors, an estimated $20K sold.

Based on aggregated 13F filings for Q1 2017.